Home › Trials › NCT06039735
Clinical trial Recruiting at 1 site Observational Ages 18 to 70

Evaluating heart health indicators in multiple myeloma treatment

Official title: Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma

Run by Qilu Hospital of Shandong University · NCT06039735 · Data updated 2026-11-12

This study is trying to find new ways to check heart health in people with multiple myeloma to help manage heart problems that might come up during their cancer treatment.

Quick facts

Study typeObservational
Ages18 Years to 70 Years
SexAll
Enrollment50 (estimated)
SponsorQilu Hospital of Shandong University
Academic / other
Locations1 site (Jinan, Shandong)
StatusRecruiting
StartedNovember 16, 2023
Main results expectedNovember 16, 2023
Study endsDecember 2028
Registry record updatedNovember 21, 2023
Trial IDNCT06039735 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18-70 diagnosed with multiple myeloma who are planning to undergo RVd induction therapy.

Probably not a fit

Patients with severe cardiovascular diseases or other systemic amyloidosis may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with multiple myeloma to identify new echocardiographic indicators that can help monitor cardiac toxicity during treatment. It aims to establish predictive models based on these indicators to improve the management of cardiovascular complications associated with chemotherapy and stem cell transplantation. The study will involve systematic follow-up monitoring of patients undergoing RVd induction therapy, assessing their heart health before, during, and after treatment. By understanding the relationship between cancer treatment and cardiovascular health, the study seeks to enhance patient care and treatment outcomes.

Why it matters

Potential benefit: If successful, this study could lead to better monitoring and management of cardiac health in multiple myeloma patients, potentially improving their overall treatment outcomes.

How similar studies have gone: While there have been studies on cardiac toxicity in cancer treatment, this approach of using echocardiographic indicators for systematic monitoring in multiple myeloma is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age 18-70 years old
2. Patients diagnosed multiple myeloma by bone marrow cytology
3. Trends to be hospitalized and treated by RVd induction therapy
4. Be able to complete at least 3-4 cycles treatment

Exclusion Criteria:

1. Simultaneously diagnosed myocardial amyloidosis or other systemic amyloidosis
2. Severe cardiovascular diseases such as myocardial infarction, heart failure, or previous surgery such as bypass grafting or valve replacement
3. Severe arrhythmia such as atrial fibrillation
4. Poor echocardiographic image quality

Where it's running

  • Qilu hospital of Shandong university
    Jinan, Shandong, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Multiple Myeloma 458Qilu Hospital of Shandong University 72
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.